Wurm David Johannes, Veiter Lukas, Ulonska Sophia, Eggenreich Britta, Herwig Christoph, Spadiut Oliver
Research Division Biochemical Engineering, Institute of Chemical Engineering, Vienna University of Technology, Vienna, Austria.
Christian Doppler Laboratory for Mechanistic and Physiological Methods for Improved Bioprocesses, Institute of Chemical Engineering, Vienna University of Technology, Vienna, Austria.
Appl Microbiol Biotechnol. 2016 Oct;100(20):8721-9. doi: 10.1007/s00253-016-7620-7. Epub 2016 May 27.
Therapeutic monoclonal antibodies are mainly produced in mammalian cells to date. However, unglycosylated antibody fragments can also be produced in the bacterium Escherichia coli which brings several advantages, like growth on cheap media and high productivity. One of the most popular E. coli strains for recombinant protein production is E. coli BL21(DE3) which is usually used in combination with the pET expression system. However, it is well known that induction by isopropyl β-D-1-thiogalactopyranoside (IPTG) stresses the cells and can lead to the formation of insoluble inclusion bodies. In this study, we revisited the pET expression system for the production of a novel antibody single-chain variable fragment (scFv) with the goal of maximizing the amount of soluble product. Thus, we (1) investigated whether lactose favors the recombinant production of soluble scFv compared to IPTG, (2) investigated whether the formation of soluble product can be influenced by the specific glucose uptake rate (q s,glu) during lactose induction, and (3) determined the mechanistic correlation between the specific lactose uptake rate (q s,lac) and q s,glu. We found that lactose induction gave a much greater amount of soluble scFv compared to IPTG, even when the growth rate was increased. Furthermore, we showed that the production of soluble protein could be tuned by varying q s,glu during lactose induction. Finally, we established a simple model describing the mechanistic correlation between q s,lac and q s,glu allowing tailored feeding and prevention of sugar accumulation. We believe that this mechanistic model might serve as platform knowledge for E. coli.
到目前为止,治疗性单克隆抗体主要在哺乳动物细胞中生产。然而,未糖基化的抗体片段也可以在大肠杆菌中产生,这具有几个优点,比如能在廉价培养基上生长且生产率高。用于重组蛋白生产的最常用大肠杆菌菌株之一是大肠杆菌BL21(DE3),它通常与pET表达系统联合使用。然而,众所周知,异丙基β-D-1-硫代半乳糖苷(IPTG)诱导会使细胞受到压力,并可能导致不溶性包涵体的形成。在本研究中,我们重新审视了用于生产新型抗体单链可变片段(scFv)的pET表达系统,目的是使可溶性产物的量最大化。因此,我们(1)研究了与IPTG相比,乳糖是否有利于可溶性scFv的重组生产,(2)研究了在乳糖诱导期间,可溶性产物的形成是否会受到特定葡萄糖摄取率(qs,glu)的影响,以及(3)确定了特定乳糖摄取率(qs,lac)和qs,glu之间的机制相关性。我们发现,与IPTG相比,即使在生长速率提高的情况下,乳糖诱导也能产生更多的可溶性scFv。此外,我们表明,在乳糖诱导期间通过改变qs,glu可以调节可溶性蛋白的产生。最后,我们建立了一个简单的模型,描述了qs,lac和qs,glu之间的机制相关性,从而实现定制补料并防止糖积累。我们相信,这个机制模型可能作为大肠杆菌的平台知识。